In brief: Health Minister Tom Binet has confirmed that Jersey’s medicines regulations are not fit for purpose, with work now under way to overhaul rules dating back to 1978. The reforms are aimed at supporting the island’s growing life sciences sector and enabling medicines made in Jersey to be exported at scale.
Outdated Rules, Emerging Industry
Jersey has ambitions to become a serious player in the life sciences and medical technologies sector, but according to Health and Social Services Minister Tom Binet, the island’s regulatory framework is currently not up to the job. The BBC reports that Binet, responding to a written question from Deputy Karen Wilson, a nurse and former health minister, confirmed that a review had found the existing rules were “not sufficiently robust.”
The minister said work had already begun to develop “enhanced” regulations that would bring Jersey into line with international standards. Among the changes being considered are updates to the 1978 Misuse of Drugs Law, a piece of legislation that, as the date suggests, has been on the books for nearly half a century. The role and duties of the chief pharmacist are also under review.
Binet described the reform programme as “necessary, proportionate, and timely,” which is the kind of language that tends to appear when a minister is gently acknowledging that things should probably have been sorted out some time ago.
Gaps in Oversight Identified
The review identified specific weaknesses in the current system. According to the BBC, Binet said there were “gaps in oversight across safety monitoring, medical devices, and research.” These are not trivial concerns: safety monitoring and medical device oversight are precisely the areas where international buyers and regulators will look first before agreeing to import anything produced in Jersey.
The minister was candid about the underlying problem, stating: “The central issue is not a lack of ambition, but limitations in governance and delivery capacity and capability.” In plain terms, Jersey wants to do this, but the structures needed to do it properly are not yet in place.
The goal, as Binet set it out, is to ensure that medicines manufactured in Jersey meet “recognised standards” so they can be exported “at scale.” That phrase, “at scale,” is doing a lot of work here. It signals that the Government is not thinking about cottage-industry production but about Jersey becoming a credible, commercially significant exporter in a highly regulated global market.
Economic Ambitions and Political Context
The minister framed the regulatory overhaul explicitly as an economic growth measure, saying it would boost the medicines and medical technologies industry. Life sciences is one of the sectors Jersey has identified as a potential diversifier alongside its well-established financial services industry, and getting the regulatory environment right is a prerequisite for attracting serious investment and operators.
The question from Deputy Karen Wilson, who brings both nursing experience and ministerial history to the subject, was a pointed one. Her background means she is well placed to probe whether the Government’s ambitions in this area are matched by the governance structures needed to deliver them safely. On the evidence of Binet’s answer, the honest response is: not yet, but work is in progress.
For Jersey residents, the practical implications are twofold. First, any strengthening of medicines regulation and safety monitoring is directly relevant to the quality of healthcare available on the island. Second, if the life sciences sector does develop as the Government hopes, it represents jobs, investment and economic activity that could benefit the wider community.
Source: BBC News
